Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Improves Cervical Cancer Screening in Low-Resource Settings

By LabMedica International staff writers
Posted on 23 Oct 2025

Access to cervical cancer screening in low- and middle-income countries remains limited, leaving many women without early detection for this life-threatening disease. More...

The lack of access to laboratories, pathologists, and reliable healthcare infrastructure hampers diagnostic capacity and timely intervention. Now, a new study has shown that artificial intelligence (AI) can analyze cervical cell samples at the primary healthcare level, improving screening accuracy and accessibility in resource-limited areas.

Researchers from Karolinska Institutet (Stockholm, Sweden), Uppsala University (Uppsala, Sweden), and collaborators conducted the study to evaluate an AI-based system for cervical cancer screening. The research was implemented through clinical projects in rural Kenya and Tanzania, in collaboration with Kinondo Kwetu Hospital and Muhimbili University of Health and Allied Sciences, involving 3,000 women. Cell samples were digitized on-site and analyzed using AI, followed by review by medical experts. Local healthcare workers were trained to operate the system, which was integrated into existing healthcare frameworks.

The study demonstrated that AI-assisted screening can significantly improve access to diagnostics where trained specialists and laboratory facilities are scarce. The findings, published in The BMJ, suggest that the system can enable earlier detection and treatment, reducing cervical cancer mortality rates. However, the technology’s effectiveness depends on the availability of supporting healthcare infrastructure, including electricity, medical supplies, and community trust.

According to the research team, AI-based diagnostics must be adapted to local conditions and integrated with national healthcare programs to ensure equitable outcomes. They also highlight the need to combine cell-based AI analysis with molecular HPV testing for more comprehensive screening approaches. Future development should focus on offline functionality and low-resource compatibility to ensure effectiveness in remote and underserved regions.

“Only a third of women worldwide have been screened for cervical cancer, even though serious disease is preventable,” says the study’s last author, Johan Lundin. “AI enables screening in low-resource settings where access to pathologists and laboratories is limited, and can shorten the time from sampling to diagnosis.”

Related Links:
Karolinska Institutet
Uppsala University


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.